These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2074519)

  • 1. Acetylation phenotypes and bladder cancer.
    Hanke J; Krajewska B
    J Occup Med; 1990 Sep; 32(9):917-8. PubMed ID: 2074519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acetylation phenotype as a biomarker of sensitivity to the carcinogenic effect of aromatic amines].
    Indulski JA; Krajewska B; Lutz W
    Med Pr; 1992; 43(5):427-35. PubMed ID: 1293477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany.
    Golka K; Prior V; Blaszkewicz M; Cascorbi I; Schöps W; Kierfeld G; Roots I; Bolt HM
    Scand J Work Environ Health; 1996 Oct; 22(5):332-8. PubMed ID: 8923605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences.
    Golka K; Prior V; Blaszkewicz M; Bolt HM
    Toxicol Lett; 2002 Mar; 128(1-3):229-41. PubMed ID: 11869833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of the slow acetylator phenotype with bladder cancer.
    Evans DA; Eze LC; Whibley EJ
    J Med Genet; 1983 Oct; 20(5):330-3. PubMed ID: 6644762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical relevance of acetylator phenotyping in 196 urothelial tumor patients].
    Schöps W; Prior V; Golka K; Blaszkewicz M; Cascorbi I; Roots I; Bolt HM; Kierfeld G
    Urologe A; 1997 Jan; 36(1):64-7. PubMed ID: 9123684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survey of the human acetylator polymorphism in spontaneous disorders.
    Evans DA
    J Med Genet; 1984 Aug; 21(4):243-53. PubMed ID: 6387123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic acetylator phenotype in bladder cancer patients.
    Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
    Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer.
    Cartwright RA; Glashan RW; Rogers HJ; Ahmad RA; Barham-Hall D; Higgins E; Kahn MA
    Lancet; 1982 Oct; 2(8303):842-5. PubMed ID: 6126711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark.
    Lower GM; Nilsson T; Nelson CE; Wolf H; Gamsky TE; Bryan GT
    Environ Health Perspect; 1979 Apr; 29():71-9. PubMed ID: 510245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
    Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
    Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular epidemiology of bladder cancer.
    Vineis P; Martone T
    Ann Ist Super Sanita; 1996; 32(1):21-7. PubMed ID: 8967722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine.
    Carreón T; Ruder AM; Schulte PA; Hayes RB; Rothman N; Waters M; Grant DJ; Boissy R; Bell DA; Kadlubar FF; Hemstreet GP; Yin S; LeMasters GK
    Int J Cancer; 2006 Jan; 118(1):161-8. PubMed ID: 16003747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
    Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
    Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA adduct levels in congenic rapid and slow acetylator mouse strains following chronic administration of 4-aminobiphenyl.
    Flammang TJ; Couch LH; Levy GN; Weber WW; Wise CK
    Carcinogenesis; 1992 Oct; 13(10):1887-91. PubMed ID: 1423849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylator phenotype in human bladder cancer.
    Miller ME; Cosgriff JM
    J Urol; 1983 Jul; 130(1):65-6. PubMed ID: 6864917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More on adducts and addicts. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer.
    Coggon D
    Hum Exp Toxicol; 1995 Jun; 14(6):538-9. PubMed ID: 8519531
    [No Abstract]   [Full Text] [Related]  

  • 19. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
    Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
    Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.
    Horai Y; Fujita K; Ishizaki T
    Eur J Clin Pharmacol; 1989; 37(6):581-7. PubMed ID: 2612554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.